Business Wire

FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction

WILMINGTON, Del.--(BUSINESS WIRE)--High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful ...
FierceBiotech

Bayer, Merck's vericiguat hits endpoint in heart failure phase 3

A phase 3 trial of Bayer and Merck’s vericiguat in heart failure patients has met its primary endpoint. The top-line readout appears to justify the risk the partners took when they moved the ...
FierceBiotech

Novartis' serelaxin misses endpoint in heart failure phase 3

Novartis’ phase 3 trial of serelaxin in acute heart failure has missed its primary endpoint. The Swiss pharma saw the 6,600-patient trial as a way to bounce back from FDA’s 2014 rejection, but instead ...
Nasdaq

Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive ...
Seeking Alpha

AskBio Presents Complete Results of Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure at European Society of Cardiology Heart Failure Meeting

First-in-human trial of AB-1002 designed to evaluate safety and preliminary efficacy in participants with New York Heart Association (NYHA) Class III heart failure Trial enrolled 11 participants in ...